Resource impact statement
No significant resource impact is anticipated
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or £9,000 per 100,000 population).
The technology is a further treatment option and is available at a similar price to the current treatment options.
A resource impact template is provided for completion at a local level.
Sotagliflozin is not yet available in the NHS, but the company anticipates that it will be available to the NHS in England and Wales within 12 months of guidance publication. Therefore, the period of time the NHS has to comply with these recommendations has been extended to within 3 months of the commercial launch of sotagliflozin in England.
This technology is commissioned by clinical commissioning groups. Providers are NHS hospital trusts, community providers and primary care providers.
This page was last updated: